1	Neutralising antibodies drive Spike mediated SARS-CoV-2 evasion
2	
3	Kemp SA ¹ *, Collier DA ^{1,2,3} *, Datir R ^{1,2,3} , Gayed S ⁴ , Jahun A ⁵ , Hosmillo M ⁵ , Ferreira IATM ^{2,3} ,
4	Rees-Spear C ¹ , Mlcochova P ^{2,3} , Ines Ushiro Lumb ⁶ , David Roberts ⁶ , Anita Chandra ^{2,3} ,
5	Temperton N ⁷ , The CITIID-NIHR BioResource COVID-19 Collaboration ⁸ , The COVID-19
6	Genomics UK (COG-UK) Consortium ⁹ , Sharrocks K ⁴ , Blane E ³ , Briggs JAG ¹⁰ , van Gils MJ ¹¹ ,
7	Smith KGC ^{2,3} , Bradley JR ^{3,12} , Smith C ¹⁴ , Goldstein RA ¹ , Goodfellow IG ⁵ , Smielewska A ^{5,13} ,
8	Skittrall JP ^{4,14,15} , Gouliouris T ⁴ , Gkrania-Klotsas E ⁴ , Illingworth CJR ^{14,16} , McCoy LE ¹ , Gupta
9	RK ^{2,3,16,17}
10	
11	¹ Division of Infection and Immunity, University College London, London, UK.
12	² Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge,
13	UK.
14	³ Department of Medicine, University of Cambridge, Cambridge, UK.
15	⁴ Department of Infectious Diseases, Cambridge University NHS Hospitals Foundation Trust,
16	Cambridge, UK.
17	⁵ Department of Pathology, University of Cambridge, Cambridge
18	⁶ Public Health England, Colindale, London, UK
19	⁷ Viral Pseudotype Unit, Medway School of Pharmacy, University of Kent, UK
20	⁸ The CITIID-NIHR BioResource COVID-19 Collaboration, see appendix 1 for author list
21 22 23	⁹ The COVID-19 Genomics UK (COG-UK) Consortium, Full list of consortium names and affiliations are in the appendix
24	¹⁰ Medical Research Council Laboratory of Molecular Biology, Cambridge, UK.
25	¹¹ Department of Medical Microbiology, Academic Medical Center, University of Amsterdam,
26	Amsterdam Institute for Infection and Immunity, Amsterdam, Netherlands
27	¹² NIHR Cambridge Clinical Research Facility, Cambridge, UK.
28	¹³ Department of Virology, Cambridge University NHS Hospitals Foundation Trust
29	¹⁴ Department of Applied Mathematics and Theoretical Physics, University of Cambridge, UK
30	¹⁵ Clinical Microbiology and Public Health Laboratory, Addenbrookes' Hospital, Cambridge, UK
31	¹⁶ MRC Biostatistics Unit, University of Cambridge, Cambridge, UK
32	¹⁷ Africa Health Research Institute, Durban, South Africa
33	NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. * equal contribution

34

- 35 Address for correspondence:
- 36 Ravindra K. Gupta
- 37 Cambridge Institute for Therapeutic Immunology and Infectious Diseases
- 38 Jeffrey Cheah Biomedical Centre
- 39 Puddicombe Way
- 40 Cambridge CB2 0AW, UK
- 41 Tel: +44 1223 331491
- 42 <u>rkg20@cam.ac.uk</u>

43

Key words: SARS-CoV-2; COVID-19; antibody escape, Convalescent plasma; neutralising antibodies; mutation; evasion; resistance; immune suppression

46

47 Abstract

48 SARS-CoV-2 Spike protein is critical for virus infection via engagement of ACE2, and amino 49 acid variation in Spike is increasingly appreciated. Given both vaccines and therapeutics are 50 designed around Wuhan-1 Spike, this raises the theoretical possibility of virus escape, 51 particularly in immunocompromised individuals where prolonged viral replication occurs. 52 Here we report fatal SARS-CoV-2 escape from neutralising antibodies in an immune 53 suppressed individual treated with convalescent plasma, generating whole genome ultradeep 54 sequences by both short and long read technologies over 23 time points spanning 101 days. 55 Little evolutionary change was observed in the viral population over the first 65 days despite 56 two courses of remdesivir. However, following convalescent plasma we observed dynamic 57 virus population shifts, with the emergence of a dominant viral strain bearing D796H in S2 58 and Δ H69/ Δ V70 in the S1 NTD of the Spike protein. As serum neutralisation waned, viruses 59 with the escape genotype diminished in frequency, before returning during a final, 60 unsuccessful course of convalescent plasma. In vitro, the Spike escape variant conferred 61 decreased sensitivity to multiple units of convalescent plasma/sera from different recovered 62 patients, whilst maintaining infectivity similar to wild type. These data reveal strong positive 63 selection on SARS-CoV-2 during convalescent plasma therapy and identify the combination of 64 Spike mutations D796H and Δ H69/ Δ V70 as a broad antibody resistance mechanism against 65 commonly occurring antibody responses to SARS-CoV-2.

66 Introduction

67 SARS-CoV-2 is an RNA betacoronavirus, with closely related viruses identified in pangolins and bats ^{1,2}. RNA viruses have inherently higher rates of mutation than DNA viruses such as 68 69 Herpesviridae³. The capacity for successful adaptation is exemplified by the Spike D614G 70 mutation, that arose in China and rapidly spread worldwide ⁴, now accounting for more than 71 90% of infections. The mutation appears to increase infectivity and transmissibility in animal 72 models ⁵. Although the SARS-CoV-2 Spike protein is critical for virus infection via engagement of ACE2, substantial Spike amino acid variation is being observed in circulating viruses ⁶. 73 74 Logically, mutations in the receptor binding domain (RBD) of Spike are of particular concern 75 due to the RBD being targeted by neutralising antibodies and therapeutic monoclonal 76 antibodies.

77

78 Deletions in the N-terminal domain (NTD) of Spike S1 are also being increasingly recognised, 79 both within hosts ⁷ and across individuals ⁸. The evolutionary basis for the emergence of 80 deletions is unclear at present, and could be related to escape from immunity or to enhanced 81 fitness/transmission. The most notable deletion in terms of frequency is Δ H69/ Δ V70. This 82 double deletion has been detected in multiple unrelated lineages, including the recent 83 'Cluster 5' mink related strain in the North Jutland region of Denmark (https://files.ssi.dk/Mink-cluster-5-short-report AFO2). There it was associated with the RBD 84 85 mutation Y453F in almost 200 individuals. Another European cluster in GISAID includes 86 Δ H69/ Δ V70 along with the RBD mutation N439K.

87

Although Δ H69/ Δ V70 has been detected multiple times, within-host emergence remains undocumented and the reasons for its selection are unknown. Here we document real time SARS-CoV-2 emergence of Δ H69/ Δ V70 in response to convalescent plasma therapy in an immunocompromised human host treated with the B cell depletion agent rituximab, demonstrating broad antibody escape in combination with the S2 mutation D796H.

93

94 **Results**

95 Clinical case history of SARS-CoV-2 infection in setting of immune-compromised host
 96 These details are available on request from the authors.

98 Negative SARS-CoV-2 specific antibodies and requirement for convalescent plasma (CP)

99 We measured blood parameters including serum SARS-CoV-2 specific antibodies over time 100 (Supplementary table 1, Supplementary Figure 1, 2). Imaging was consistent with COVID-19 101 disease (Supplementary Figure 3). Total serum antibodies to SARS-CoV-2 were tested at days 102 44 and 50 by S protein immunoassay (Siemens). Results were negative. Three units (200mL 103 each) of convalescent plasma (CP) from three independent donors were obtained from the 104 NHS Blood and Transfusion Service and administered on compassionate use basis. These had 105 been assayed for antibody titres using the validated Euroimmun assay (Supplementary figure 106 3). Patient serum was subsequently positive for SARS-CoV-2 specific antibodies by S protein 107 immunoassay (Siemens) in the hospital diagnostic laboratory on days 68, 90 and 101.

108

109 Virus genomic comparative analysis of 23 sequential respiratory samples over 101 days

110 The majority of samples were respiratory samples from nose and throat or endotracheal 111 aspirates during the period of intubation. Ct values ranged from 16-34 and all 23 respiratory 112 samples were successfully sequenced by standard long read approach as per the ARTIC 113 protocol implemented by COG-UK; of these 20 additionally underwent short-read deep 114 sequencing using the Illumina platform. There was generally good agreement between the 115 methods, though as expected nanopore demonstrated greater error at low variant 116 frequencies (<10%) (Supplementary Figure 4). We detected no evidence of recombination, 117 based on two independent methods.

118

119 Maximum likelihood analysis of patient-derived whole genome consensus sequences 120 demonstrated clustering with other local sequences from the same region (Figure 1A). The 121 infecting strain was assigned to lineage 20B bearing the D614G Spike variant. Environmental 122 sampling showed evidence of virus on surfaces such as telephone and call bell but not in air 123 on days 59, 92 and 101. Sequencing of these surface viruses showed clustering with those 124 derived from the respiratory tract (Figure 1B). All samples were consistent with having arisen 125 from a single viral population. In our phylogenetic analysis, we included sequential sequences 126 from three other local patients identified with persistent viral RNA shedding over a period of 127 4 weeks or more (Supplementary Table 2). Viruses from these individuals showed very little 128 divergence in comparison to the case patient (Figure 1B) and none showed amino acid 129 changes in Spike over time. We additionally inferred a maximum likelihood phylogeny

comparing sequences from these three local individuals and two long term immunosuppressed SARS-CoV-2 'shedders' recently reported^{7,9}, (Figure 1B). While the sequences from Avanzato et al showed a pattern of evolution more similar to two of the three other local patients, the case patient showed significant diversification with a mutation rate of 30 per year (Supplementary table 2).

135

136 Further investigation of the sequence data suggested the existence of an underlying structure 137 to the viral population in our patient, with samples collected at days 93 and 95 being rooted 138 within, but significantly divergent from the original population (Figure 1B and 2A). The 139 relationship of the divergent samples to those at earlier time points rules out the possibility 140 of superinfection. The increased divergence of sequences does not necessarily indicate 141 selection; a spatially compartmentalised subset of viruses, smaller in number than the main 142 viral population, would be expected to evolve more quickly than the main population due to 143 the increased effect of genetic drift ^{10,11}.

144

145 Virus population structure changes following convalescent plasma and remdesivir

146 All samples tested positive by RT-PCR and there was no sustained change in Ct values 147 throughout the 101 days following the first two courses of remdesivir (days 41 and 54), or the 148 first two units of convalescent plasma (days 63 and 65). According to nanopore data, no 149 polymorphisms occurred over the first 60 days at consensus level (Figure 2A). However, short 150 read deep sequence Illumina data revealed minority polymorphisms in the viral population 151 during this period (Figure 2B). For example, T39I in ORF7a reached a majority frequency of 152 77% on day 44, arising de novo and increased in frequency during the first period of the 153 infection (Supplementary Figure 6).

154

155 In contrast to the early period of infection, between days 66 and 82 a dramatic shift in virus 156 population structure was observed, with the near-fixation of D796H in S2 along with 157 Δ H69/ Δ V70 in the S1 N-terminal domain (NTD) at day 82. This was identified in a nose and 158 throat swab sample with high viral load as indicated by Ct of 23 (Figure 3). The deletion was 159 not detected at any point prior to the day 82 sample, even as minority variants by short read 160 deep sequencing.

On Days 86 and 89, viruses collected were characterised by the Spike mutations Y200H and T240I, with the deletion/mutation pair observed on day 82 having fallen to very low frequency. Sequences collected on these days formed a distinct branch at the bottom of the phylogeny in Figure 3, but were clearly associated with the remainder of the samples, suggesting that they did not result from superinfection (Supplementary Figure 7), and further were not significantly divergent from the bulk of the viral population (Supplementary Figure 5).

169

170 Sequencing of a nose and throat swab sample at day 93 again showed D796H along with 171 Δ H69/ Δ V70 at <10% abundance, along with an increase in a virus population characterised 172 by Spike mutations P330S at the edge of the RBD and W64G in S1 NTD. This new lineage 173 reached near 100% abundance at day 93. Viruses with the P330S variant were detected in 174 two independent samples from different sampling sites, ruling out the possibility of 175 contamination. The divergence of these samples from the remainder of the population 176 (Figure 3B), noted above, suggests the possibility of their resulting from the stochastic 177 emergence, in the upper respiratory tract, of a previously unobserved subpopulation of 178 viruses (Supplementary Figure 5).

179

Following the third course of remdesivir (day 93) and third CP (day 95), we observed a re-180 181 emergence of the D796H + Δ H69/ Δ V70 viral population. The inferred linkage of D796H and 182 Δ H69/ Δ V70 was maintained as evidenced by the highly similar frequencies of the two 183 variants, suggesting that the third unit of CP led to the re-emergence of this viral strain under 184 renewed positive selection. Ct values remained low throughout this period with hyperinflammation, eventually leading to multi-organ failure and death at day 102. The 185 186 repeated increase in frequency of the novel viral strain during CP therapy strongly supports 187 the hypothesis that the deletion/mutation combination conferred antibody escape 188 properties.

189

190 ΔH69/ΔV70 + D796H confers impaired neutralisation by multiple convalescent plasma units

191 and sera from recovered COVID-19 patients

192 Using lentiviral pseudotyping we expressed wild type and Δ H69/ Δ V70 + D796H mutant Spike

193 protein in enveloped virions and compared neutralisation activity of CP against these viruses.

194 This system has been shown to give similar results to replication competent virus^{12,13}. We first 195 tested infection capacity over a single round of infection and found that Δ H69/ Δ V70 + D796H 196 had similar infectivity to wild type (both in a D614G background, Figure 4A, B). The 197 Δ H69/ Δ V70 + D796H mutant was partially resistant to the first two CP units (Figure 4C, Table 198 1A). In addition, patient derived serum from days 64 and 66 (one day either side of CP2 199 infusion) similarly showed lower potency against the mutant (Figure 4C, Table 1A). The 200 repeated observation of D796H + Δ H69/ Δ V70 emergence and positive selection strengthens 201 the hypothesis that these variants were the key drivers of antibody escape. Experimentally, 202 the D796H + Δ H69/ Δ V70 mutant also demonstrated reduced susceptibility to the CP3 203 administered on day 95, explaining its re-emergence (Figure 4C, Table 1A).

204

205 Given reduced susceptibility of the mutants to at least two units of CP, and the expansion of 206 sequences bearing Δ H69/ Δ V70, we hypothesised that this represented a broad escape 207 mechanism. We therefore screened antiviral neutralisation activity in sera from five 208 recovered patients against the mutant and wild type viruses (Figure 4D). We observed that 209 the mutant was indeed significantly less susceptible to four of five randomly selected sera, 210 with the fifth showing reduced susceptibility that did not reach statistical significance (Table 211 1B). Fold change reductions in susceptibility of the mutant were as high as ten-fold compared 212 to wild type (Table 1B).

213

In order to probe the impact of the D796H and Δ H69/ Δ V70 mutations on potency of monoclonal antibodies (mAbs) targeting Spike, we screened neutralisation activity of a panel of seven neutralizing mAbs across a range of epitope clusters¹³ (Figure 4E). We observed no differences in neutralisation between single mutants and wild type, suggesting that the mechanism of escape was likely outside these epitopes.

219

In order to understand the mechanisms that might confer resistance to antibodies we examined a published Spike structure and annotated it our residues of interest (Figure 5). This analysis showed that Δ H69/ Δ V70 is in a disordered, glycosylated loop at the very tip of the NTD, and therefore could alter binding of antibodies. Δ H69/V70 is close to the binding site of the polyclonal antibodies derived from COV57 plasma, indicating the sera tested here may contain similar antibodies ^{14,15}. D796H is in an exposed loop in S2 (Figure 5), and appears

to be in a region frequently targeted by antibodies¹⁶, despite mutations at position 796 being
rare (Supplementary table 4).

228

229 Discussion

230 Here we have documented a repeated evolutionary response by SARS-CoV-2 against antibody 231 therapy during the course of a persistent and eventually fatal infection in an 232 immunocompromised host. The observation of potential selection for specific variants 233 coinciding with the presence of antibodies from convalescent plasma is supported by the 234 experimental finding of reduced susceptibility of these viruses to plasma. Further, we were 235 able to document real-time emergence of a variant Δ H69/ Δ V70 in the NTD of Spike that has 236 been increasing in frequency in Europe. In the case we report that it was not clear that the 237 emergence of the antibody escape variant was the primary reason for treatment failure. 238 However, given that both vaccines and therapeutics are aimed at Spike, our study raises the 239 possibility of virus evasion, particularly in immune suppressed individuals where prolonged 240 viral replication occurs.

241

242 Our observations represent a very rare insight, and only possible due to lack of antibody 243 responses in the individual following administration of the B cell depleting agent rituximab 244 for lymphoma, and an intensive sampling course undertaken due to concerns about 245 persistent shedding and risk of nosocomial transmission. Persistent viral replication and the 246 failure of antiviral therapy allowed us to define the viral response to convalescent plasma, 247 similar to a recent report on asymptomatic long term shedding with four sequences over 105 248 days⁹, although the reported shifts in genetic composition of the viral population could not 249 be explained phenotypically. Another common finding is the very low neutralisation activity 250 in serum post transfusion of CP with waning as expected. Apart from the difference in the 251 outcome of infection (severe, fatal disease versus asymptomatic disease and clearance), 252 critically important differences in our study include: 1. The intensity of sampling and use of 253 both long and short read sequencing to verify variant calls, thereby providing a unique 254 scientific resource for longitudinal population genetic analysis. 2. The close alignment 255 between the genetic composition of the viral population and CP administration, with an experimentally verified resistant strain emerging, falling to low frequency, and then rising 256 257 again under CP selection. 3. Real time detection of emergence of a variant, Δ H69/ Δ V70, that

is increasing in frequency in Europe, and shown here to affect neutralization by multipleCOVID-19 patient derived sera.

260

261 We have noted in our analysis the potential influence of compartmentalised viral replication 262 upon the sequences recovered in upper respiratory tract samples. Both population genetic 263 and small animal studies have shown a lack of reassortment between influenza viruses within 264 a single host during an infection, suggesting that acute respiratory viral infection may be characterised by spatially distinct viral populations^{17,18}. In the analysis of data it is important 265 266 to distinguish genetic changes which occur in the primary viral population from apparent 267 changes that arise from the stochastic observation of spatially distinct subpopulations in the 268 host. While the samples we observe on days 93 and 95 of infection are genetically distinct 269 from the others, the remaining samples are consistent with arising from a consistent viral 270 population, supporting the finding of a reversion and subsequent regain of antibody 271 resistance. We note that in a study of SARS-CoV-2, Choi et al reported the detection in post 272 mortem tissue of viral RNA not only in lung tissue, but also in the spleen, liver and heart⁷. 273 Mixing of virus from different compartments, for example via blood, or movement of 274 secretions from lower to upper respiratory tract, could lead to fluctuations in viral populations 275 at particular sampling sites. Experiments in animal models with sampling of different 276 replication sites could allow a better understanding of SARS-CoV-2 population genetics and 277 enable prediction of escape variants following antibody based therapies.

278

This is a single case report and therefore limited conclusions can be drawn about generalisability.

In addition to documenting the emergence of SARS-CoV-2 Spike Δ H69/ Δ V70 + D796H *in vivo*, 281 282 conferring broad reduction in susceptibility to serum/plasma polyclonal, but no effect on a 283 set of predominantly RBD-targeting monoclonal antibodies, these data highlight that 284 infection control measures need to be specifically tailored to the needs of immunocompromised patients. The data also highlight caution in interpretation of CDC 285 286 guidelines that recommend 20 days as the upper limit of infection prevention precautions in immune compromised patients who are afebrile¹⁹. Due to the difficulty with culturing clinical 287 288 isolates, use of surrogates for infectious virus such as sgRNA are warranted²⁰. However, where 289 detection of ongoing viral evolution is possible, this serves as a clear proxy for the existence

of infectious virus. In our case we detected environmental contamination whilst in a single
 occupancy room and the patient was moved to a negative-pressure high air-change infectious
 disease isolation room.

The clinical efficacy of CP has been called into question recently²¹, and our data suggest caution in use of CP in patients with immune suppression of both T cell and B cell arms. In such cases, the antibodies administered have little support from cytotoxic T cells, thereby reducing chances of clearance and raising the potential for escape mutations. Whilst we await further data, CP administered for clinical need in immune suppression, should ideally be undertaken in single occupancy rooms with enhanced infection control precautions, including

- 300 SARS-CoV-2 environmental sampling and real-time sequencing.

- Table 1: Neutralisation activity of convalescent plasma and patient sera taken in between CP doses against SARS-CoV-2 viral variants observed in A. patient case. B. five patients with recovered COVID-19. Shown are IC50 dilution titres - the CP or serum reciprocal dilution at which 50% of virus infectivity is lost against wild type (baseline) or D796H + Δ 69/70 mutant Spike protein expressed on the surface of a lentiviral particle. Fold change is the difference between the two viruses, and values below 1 indicate that the D796H/ Δ 69/70 mutant is less sensitive to the CP or serum. Only the D66 serum sample failed to demonstrate significantly higher resistance of the D796H/ Δ 69/70 mutant.

Α.	IC50 as reciprocal dilution (95% CI)		
	WT	D796H + ∆69/70	Fold Change IC50 (95% CI)
CP1	2480.0 (2104.0 - 2965.0)	924.2 (634.1 - 1316.0)	0.37 (0.24 - 0.56)
D64 serum	163.7 (106.6 - 256.4)	55.6 (29.5 - 100.6)	0.27 (0.12 - 0.77)
CP2	447.1 (305.2 - 670.1)	196 (129.8 - 294.7)	0.47 (0.25 - 0.86)
D66 serum	175.7 (90.7 - 410.4)	85.5 (48.2 - 149.8)	0.82 (0.29 - 1.96)
CP3	280.2 (172.8 - 480.3)	115 (75.0 - 175.5)	0.47 (0.24 - 0.91)

В.	IC50 as reciprocal dilution (95% CI)		
	WT	D796H + ∆69/70	Fold Change IC50 (95% CI)
Serum 1	994.1 (852.7-1159.0)	755.8 (426.7-1269.0)	0.71 (0.39-1.33)
Serum 2	2107.0 (1680.0-2662.0)	1045.0 (745.9-1387.0)	0.42 (0.27-0.70)
Serum 3	3241.0 (2377.0-4643.0)	347.4 (234.4-505.4)	0.11 (0.07-0.17)
Serum 4	17368.0 (14357.0-22130.0)	2965.0 (2287.0-3767.0)	0.26 (0.20-0.32)
Serum 5	52735.0 (34276.0-93957.0)	3871.0 (3525.0-4252.0)	0.20 (0.17-0.24)

343 Ethics

The study was approved by the East of England – Cambridge Central Research Ethics Committee (17/EE/0025). The patient and family provided written informed consent. Additional controls with COVID-19 were enrolled to the NIHR BioResource Centre Cambridge under ethics review board (17/EE/0025).

348

349 Acknowledgements

350 We are immensely grateful to the patient and family. We would also like to thank the staff at 351 CUH and the NIHR Cambridge Clinical Research Facility. We would like to thank Dr Ruthiran 352 Kugathasan and Professor Wendy Barclay for helpful discussions and Dr Martin Curran, Dr 353 William Hamilton and Dr. Dominic Sparkes. We would like to thank Prof Andres Floto and Prof 354 Ferdia Gallagher. We thank Dr James Voss for the kind gift of HeLa cells stably expressing 355 ACE2. COG-UK is supported by funding from the Medical Research Council (MRC) part of UK 356 Research & Innovation (UKRI), the National Institute of Health Research (NIHR) and Genome 357 Research Limited, operating as the Wellcome Sanger Institute. RKG is supported by a 358 Wellcome Trust Senior Fellowship in Clinical Science (WT108082AIA). LEM is supported by a 359 Medical Research Council Career Development Award (MR/R008698/1). SAK is supported by 360 the Bill and Melinda Gates Foundation via PANGEA grant: OPP1175094. DAC is supported by 361 a Wellcome Trust Clinical PhD Research Fellowship. CJRI acknowledges MRC funding (ref: 362 MC UU 00002/11). This research was supported by the National Institute for Health 363 Research (NIHR) Cambridge Biomedical Research Centre, the Cambridge Clinical Trials Unit 364 (CCTU) and by the UCL Coronavirus Response Fund and made possible through generous 365 donations from UCL's supporters, alumni and friends (LEM). JAGB is supported by the Medical 366 Research Council (MC UP 1201/16).

367

368 Author contributions

- 369 Conceived study: RKG, SAK, DAC, AS, TG, EGK
- 370 Designed experiments: RKG, SAK, DAC, LEM, JAGB, EGK, AC, NT, AC, CS
- 371 Performed experiments: SAK, DAC, LEM, RD, CRS, AJ, IATMF, KS, TG, CJRI, BB, JS, MJvG
- 372 Interpreted data: RKG, SAK, DAC, PM, LEM, JAGB, PM, SG, KS, TG, JB, KGCS, IG, CJRI, JAGB,
- 373 IUL, DR, JS, BB
- 374

375 Methods

376 Clinical Sample Collection and Next generation sequencing

377 Serial samples were collected from the patient periodically from the lower respiratory tract 378 (sputum or endotracheal aspirate), upper respiratory tract (throat and nasal swab), and from 379 stool. Nucleic acid extraction was done from 500µl of sample with a dilution of MS2 380 bacteriophage to act as an internal control, using the easyMAG platform (Biomerieux, Marcy 381 LEtoile) according to the manufacturers' instructions. All samples were tested for presence of 382 SARS-CoV-2 with a validated one-step RT q-PCR assay developed in conjunction with the Public Health England Clinical Microbiology ²². Amplification reaction were all performed on 383 384 a Rotorgene[™] PCR instrument. Samples which generated a CT of ≤36 were considered to be 385 positive.

386

387 Sera from recovered patients in the COVIDx study²³ were used for testing of neutralisation
 388 activity by SARS-CoV-2 mutants.

389

390 For viral genomic sequencing, total RNA was extracted from samples as described. Samples 391 were sequenced using MinION flow cells version 9.4.1 (Oxford Nanopore Technologies) 392 following the ARTICnetwork V3 protocol 393 (https://dx.doi.org/10.17504/protocols.io.bbmuik6w) and BAM files assembled using the 394 ARTICnetwork assembly pipeline (https://artic.network/ncov-2019/ncov2019-395 bioinformatics-sop.html). A representative set of 10 sequences were selected and also 396 sequenced using the Illumina MiSeq platform. Amplicons were diluted to 2 ng/µl and 25 µl 397 (50 ng) were used as input for each library preparation reaction. The library preparation used 398 KAPA Hyper Prep kit (Roche) according to manufacturer's instructions. Briefly, amplicons 399 were end-repaired and had A-overhang added; these were then ligated with 15mM of NEXTflex 400 DNA Barcodes (Bio Scientific, Texas, USA). Post-ligation products were cleaned using AMPure 401 beads and eluted in 25 μ l. Then, 20 μ l were used for library amplification by 5 cycles of PCR. 402 For the negative controls, 1ng was used for ligation-based library preparation. All libraries 403 were assayed using TapeStation (Agilent Technologies, California, USA) to assess fragment 404 size and quantified by QPCR. All libraries were then pooled in equimolar accordingly. Libraries 405 were loaded at 15nM and spiked in 5% PhiX (Illumina, California, USA) and sequenced on one

406 MiSeq 500 cycle using a Miseq Nano v2 with 2x 250 paired-end sequencing. A minimum of 407 ten reads were required for a variant call.

408

409 Bioinformatics Processes

410 For long-read sequencing, genomes were assembled with reference-based assembly and a 411 curated bioinformatics pipeline with 20x minimum coverage across the whole-genome ²⁴. For 412 short-read sequencing, FASTQs were downloaded, poor-quality reads were identified and 413 removed, and both Illumina and PHiX adapters were removed using TrimGalore v0.6.6²⁵. 414 Trimmed paired-end reads were mapped to the National Center for Biotechnology 415 Information SARS-CoV-2 reference sequence MN908947.3 using MiniMap2-2.17 with 416 arguments -ax and sr²⁶. BAM files were then sorted and indexed with samtools v1.11 and PCR 417 optical duplicates removed using Picard (http://broadinstitute.github.io/picard). Single 418 nucleotide polymorphisms (SNPs) were called using Freebayes v1.3.2²⁷ with a ploidy setting 419 of 1, minimum allele frequency of 0.20 and a minimum depth of five reads. Finally, a 420 consensus sequences of nucleic acids with a minimum whole-genome coverage of at least 421 20× were generated with BCFtools using a 0% majority threshold.

422

423 *Phylogenetic Analysis*

424 All available full-genome SARS-CoV-2 sequences were downloaded from the GISAID database (http://gisaid.org/) ²⁸ on 17th September. Duplicate and low-quality sequences (>5% N 425 426 regions) were removed, leaving a dataset of 138,472 sequences with a length of >29,000bp. 427 All sequences were sorted by name and only sequences sequenced with United Kingdom / 428 England identifiers were retained. From this dataset, a subset of 250 sequences were 429 randomly subsampled using seqtk (https://github.com/lh3/seqtk). These 250 sequences were 430 aligned to the 23 patient sequences, as well as three other control patients (persistent long-431 term shedders from the same hospital) (Supplementary Table 2) and the SARS-CoV-2 432 reference strain MN908947.3, using MAFFT v7.473 with automatic flavour selection ²⁹. Major 433 SARS-CoV-2 clade memberships were assigned to all sequences using the Nextclade server 434 v0.8 (https://clades.nextstrain.org/).

435

436 Maximum likelihood phylogenetic trees were produced using the above curated dataset using
 437 IQ-TREE v2.1.2 ³⁰. Evolutionary model selection for trees were inferred using ModelFinder ³¹

and trees were estimated using the GTR+F+I model with 1000 ultrafast bootstrap replicates
³². All trees were visualised with Figtree v.1.4.4 (<u>http://tree.bio.ed.ac.uk/software/figtree/</u>),
rooted on the SARS-CoV-2 reference sequence and nodes arranged in descending order.
Nodes with bootstraps values of <50 were collapsed using an in-house script.

442

443 A time tree indicating temporal divergence was inferred using TreeTime v0.75³³. For this a 444 further subsample of 100 sequences from the multiple sequence alignment used to make the 445 maximum likelihood tree were selected, which represented sequences belonging to 446 NextStrain clade 20B. This included the 23 patient genomes, all genomes from two of the 447 three long-term shedders (one was excluded as it belonged to NextStrain clade 19A), 75 448 subsampled Cambridge sequences, and the SARS-CoV-2 reference strain MN908947.3. All 449 sequences were re-aligned using MAFFT v7.473 with automatic flavour selection ²⁹ and used 450 as input.

451

452 Molecular substitution (clock) rates for the index patient, as well as three long-term shedders 453 and two recently described immunocompromised patients from literature, were estimated 454 using BEAST v2.6.3 ³⁴ using a HKY substitution model with 4 rate categories drawn from a 455 gamma distribution, a strict clock and a coalescent exponential population tree prior. MCMC 456 was run for 100 million iterations excluding a 15% burn-in. Tracer v1.7.1 was used to analyse 457 the BEAST trace in order extract the clock rate and ensure convergence had occurred.

458

459 In-depth allele frequency variant calling

The SAMFIRE package³⁵ was used to call allele frequency trajectories from BAM file data. 460 461 Reads were included in this analysis if they had a median PHRED score of at least 30, trimming 462 the ends of reads to achieve this if necessary. Nucleotides were then filtered to have a PHRED 463 score of at least 30; reads with fewer than 30 such reads were discarded. Distances between 464 sequences, accounting for low-frequency variant information, was also conducted using SAMFIRE. The sequence distance metric, described in an earlier paper ¹¹, combines allele 465 466 frequencies across the whole genome. Where L is the length of the genome, we define q(t)467 as a 4 x L element vector describing the frequencies of each of the nucleotides A, C, G, and T 468 at each locus in the viral genome sampled at time t. For any given locus i in the genome we

calculate the change in allele frequencies between the times t₁ and t₂ via a generalisation of
 the Hamming distance

471

472
$$d(q_i(t_1), q_i(t_2)) = \frac{1}{2} \sum_{a \in \{A, C, G, T\}} |q_i^a(t_1) - q_i^a(t_2)|$$

473

where the vertical lines indicate the absolute value of the difference. These statistics werethen combined across the genome to generate the pairwise sequence distance metric

477
$$D(\boldsymbol{q}(t_1), \boldsymbol{q}(t_2)) = \sum_i d(q_i(t_1), q_i(t_2))$$

478

The Mathematica software package was to conduct a regression analysis of pairwise sequence distances against time, leading to an estimate of a mean rate of within-host sequence evolution. In contrast to the phylogenetic analysis, this approach assumed the samples collected on days 93 and 95 to arise via stochastic emission from a spatially separated subpopulation within the host, leading to a lower inferred rate of viral evolution for the bulk of the viral population.

485

486 Inference of selection

Under the assumption of a large effective population size, a deterministic one-locus model of selection was fitted to genome sequence data describing changes in the frequency of the variant T39I. Where q(t) represents the frequency of a single variant at time t, we used a maximum likelihood method to infer the initial variant frequency at time t=1, and the selection coefficient s, for times from the initial time point to the disappearance of the variant from the population. Specifically, where n(t_i) and N(t_i) were the number of observations of the variant and the total read depth at that locus at time t_i, we fitted the model

494

495
$$q(t) = \frac{q(1)e^{st}}{1-q(1)+q(1)e^{st}}$$

496

497 so as to maximise the binomial likelihood

498

499
$$L = \sum_{i} \log \binom{N_i}{n_i} q(t_i)^{n_i} (1 - q(t_i))^{N - n_i}$$

500 A similar calculation was performed to estimate the mean effective selection (incorporating 501 intrinsic selection for the variant plus linkage with other selected alleles) acting upon the 502 variant D796H during the final period of CP therapy. In this case selection was modelled as 503 being time-dependent, kicking in with the administration of therapy. We fitted the model: 504

505
$$q(t) = q \text{ if } t < \tau$$
$$q(t) = \frac{q e^{s(t-\tau)}}{1 - q + q e^{s(t-\tau)}} \text{ if } t \ge \tau$$

506

507 to the data, setting τ = 95.

508

509 **Recombination Detection**

510 All sequences were tested for potential recombination, as this would impact on evolutionary 511 estimates. Potential recombination events were explored with nine algorithms (RDP, MaxChi, 512 SisScan, GeneConv, Bootscan, PhylPro, Chimera, LARD and 3SEQ), implemented in RDP5 with default settings ³⁶. To corroborate any findings, ClonalFrameML v1.12 ³⁷ was also used to infer 513 514 recombination breakpoints. Neither programs indicated evidence of recombination in our 515 data. 516

517 Structural Viewing

518 The Pymol Molecular Graphics System v2.4.0 (https://github.com/schrodinger/pymol-open-

519 source/releases) was used to map the location of the four spike mutations of interested onto

520 a SARS-CoV-2 spike structure visualised by Wrobel et al (PDB: 6ZGE) ³⁸.

521

522 Generation of Spike mutants

523 Amino acid substitutions were introduced into the D614G pCDNA SARS-CoV-2 Spike plasmid

524 as previously described³⁹ using the QuikChange Lightening Site-Directed Mutagenesis kit,

525 following the manufacturer's instructions (Agilent Technologies, Inc., Santa Clara, CA).

527 Pseudotype virus preparation

Viral vectors were prepared by transfection of 293T cells by using Fugene HD transfection reagent (Promega). 293T cells were transfected with a mixture of 11ul of Fugene HD, 1µg of pCDNAΔ19Spike, 1µg of p8.91 HIV-1 gag-pol expression vector^{40,41}, and 1.5µg of pCSFLW (expressing the firefly luciferase reporter gene with the HIV-1 packaging signal). Viral supernatant was collected at 48 and 72h after transfection, filtered through 0.45µm filter and stored at -80°C. The 50% tissue culture infectious dose (TCID50) of SARS-CoV-2 pseudovirus was determined using Steady-Glo Luciferase assay system (Promega).

535

536 RT activity in virion containing supernatant was measured as previously described.

537

538 Serum/plasma pseudotype neutralisation assay

539 Spike pseudotype assays have been shown to have similar characteristics as neutralisation

540 testing using fully infectious wild type SARS-CoV-2¹².Virus neutralisation assays were

541 performed on 293T cell transiently transfected with ACE2 and TMPRSS2 using SARS-CoV-2

542 Spike pseudotyped virus expressing luciferase⁴². Pseudotyped virus was incubated with

serial dilution of heat inactivated human serum samples or convalescent plasma in duplicate

544 for 1h at 37°C. Virus and cell only controls were also included. Then, freshly trypsinized 293T

545 ACE2/TMPRSS2 expressing cells were added to each well. Following 48h incubation in a 5%

546 CO₂ environment at 37°C, the luminescence was measured using Steady-Glo Luciferase

547 assay system (Promega).

548

549 *mAb pseudotype neutralisation assay*

550 Virus neutralisation assays were performed on HeLa cells stably expressing ACE2 and using

551 SARS-CoV-2 Spike pseudotyped virus expressing luciferase as previously described⁴³.

552 Pseudoyped virus was incubated with serial dilution of purified mAbs¹³ in duplicate for 1h at

553 37°C. Then, freshly trypsinized HeLa ACE2- expressing cells were added to each well.

554 Following 48h incubation in a 5% CO₂ environment at 37°C, the luminescence was

555 measured using Bright-Glo Luciferase assay system (Promega) and neutralization calculated

relative to virus only controls. IC50 values were calculated in Graphpad Prism.

medRxiv preprint doi: https://doi.org/10.1101/2020.12.05.20241927; this version posted December 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

558 References

- 559 1 Zhang, T., Wu, Q. & Zhang, Z. Probable pangolin origin of SARS-CoV-2 associated with the 560 COVID-19 outbreak. *Current Biology* (2020).
- 561
 2
 Xiao, K. *et al.* Isolation of SARS-CoV-2-related coronavirus from Malayan pangolins. *Nature*

 562
 583, 286-289, doi:10.1038/s41586-020-2313-x (2020).
- 563
 3
 Sanjuán, R. & Domingo-Calap, P. Mechanisms of viral mutation. *Cell Mol Life Sci* **73**, 4433

 564
 4448, doi:10.1007/s00018-016-2299-6 (2016).
- 5654Korber, B. *et al.* Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases566Infectivity of the COVID-19 Virus. *Cell*, doi:10.1016/j.cell.2020.06.043 (2020).
- 5675Yurkovetskiy, L. *et al.* Structural and Functional Analysis of the D614G SARS-CoV-2 Spike568Protein Variant. *Cell* **183**, 739-751 e738, doi:10.1016/j.cell.2020.09.032 (2020).
- 569 6 Korber, B. *et al.* Tracking changes in SARS-CoV-2 Spike: evidence that D614G increases 570 infectivity of the COVID-19 virus. *Cell* **182**, 812-827. e819 (2020).
- 5717Choi, B. *et al.* Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host. N572*Engl J Med*, doi:10.1056/NEJMc2031364 (2020).
- 5738McCarthy, K. R. *et al.* Natural deletions in the SARS-CoV-2 spike glycoprotein drive antibody574escape. *bioRxiv*, 2020.2011.2019.389916, doi:10.1101/2020.11.19.389916 (2020).
- 5759Avanzato, V. A. *et al.* Case Study: Prolonged infectious SARS-CoV-2 shedding from an
asymptomatic immunocompromised cancer patient. *Cell* (2020).
- 57710Wright, S. Size of population and breeding structure in relation to evolution. Science, 430-431578(1938).
- 57911Lumby, C. K., Zhao, L., Breuer, J. & Illingworth, C. J. A large effective population size for
established within-host influenza virus infection. *Elife* 9, doi:10.7554/eLife.56915 (2020).
- 58112Schmidt, F. *et al.* Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and
chimeric viruses. 2020.2006.2008.140871, doi:10.1101/2020.06.08.140871 %J bioRxiv (2020).
- 58313Brouwer, P. J. M. *et al.* Potent neutralizing antibodies from COVID-19 patients define multiple584targets of vulnerability. *Science* **369**, 643-650, doi:10.1126/science.abc5902 (2020).
- 585 14 Robbiani, D. F. *et al.* Convergent antibody responses to SARS-CoV-2 in convalescent 586 individuals. *Nature* **584**, 437-442, doi:10.1038/s41586-020-2456-9 (2020).
- 58715Barnes, C. O. *et al.* Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal588Common Epitopes and Recurrent Features of Antibodies. *Cell* **182**, 828-842 e816,589doi:10.1016/j.cell.2020.06.025 (2020).
- 590 16 Shrock, E. *et al.* Viral epitope profiling of COVID-19 patients reveals cross-reactivity and 591 correlates of severity. *Science*, doi:10.1126/science.abd4250 (2020).
- 59217Sobel Leonard, A. *et al.* The effective rate of influenza reassortment is limited during human593infection. *PLoS pathogens* **13**, e1006203, doi:10.1371/journal.ppat.1006203 (2017).
- 59418Richard, M., Herfst, S., Tao, H., Jacobs, N. T. & Lowen, A. C. Influenza A Virus Reassortment Is595Limited by Anatomical Compartmentalization following Coinfection via Distinct Routes.596Journal of virology 92, doi:10.1128/JVI.02063-17 (2018).
- 59719CDC. Discontinuation of Transmission-Based Precautions and Disposition of Patients with598COVID-19inHealthcareSettings(Interim Guidance),599<<u>https://www.cdc.gov/coronavirus/2019-ncov/hcp/disposition-hospitalized-patients.html</u>>600(2020).
- 60120Boshier, F. A. T. *et al.* Remdesivir induced viral RNA and subgenomic RNA suppression, and602evolution of viral variants in SARS-CoV-2 infected patients. *medRxiv*,6032020.2011.2018.20230599, doi:10.1101/2020.11.18.20230599 (2020).
- 60421Simonovich, V. A. *et al.* A Randomized Trial of Convalescent Plasma in Covid-19 Severe605Pneumonia. N Engl J Med, doi:10.1056/NEJMoa2031304 (2020).
- 60622Meredith, L. W. *et al.* Rapid implementation of SARS-CoV-2 sequencing to investigate cases of607health-care associated COVID-19: a prospective genomic surveillance study. The Lancet608Infectious Diseases 20, 1263-1272, doi:10.1016/S1473-3099(20)30562-4 (2020).

medRxiv preprint doi: https://doi.org/10.1101/2020.12.05.20241927; this version posted December 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

60923Collier, D. A. *et al.* Point of Care Nucleic Acid Testing for SARS-CoV-2 in Hospitalized Patients:610A Clinical Validation Trial and Implementation Study. *Cell Rep Med*, 100062,611doi:10.1016/j.xcrm.2020.100062 (2020).

612 24 Loman, N., Rowe, W. & Rambaut, A. (v1, 2020).

- 61325Martin, M. Cutadapt removes adapter sequences from high-throughput sequencing reads.614EMBnet. journal 17, 10-12 (2011).
- 61526Li, H. Minimap2: pairwise alignment for nucleotide sequences. Bioinformatics (Oxford,616England) 34, 3094-3100, doi:10.1093/bioinformatics/bty191 (2018).
- 61727Garrison, E. & Marth, G. Haplotype-based variant detection from short-read sequencing. arXiv618preprint arXiv:1207.3907 (2012).
- 61928Shu, Y. & McCauley, J. GISAID: Global initiative on sharing all influenza data from vision to620reality. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European621communicable disease bulletin 22, 30494, doi:10.2807/1560-7917.ES.2017.22.13.30494622(2017).
- Katoh, K. & Standley, D. M. MAFFT Multiple Sequence Alignment Software Version 7:
 Improvements in Performance and Usability. *Molecular Biology and Evolution* **30**, 772-780,
 doi:10.1093/molbev/mst010 (2013).
- 62630Minh, B. Q. *et al.* IQ-TREE 2: New Models and Efficient Methods for Phylogenetic Inference in627the Genomic Era. *Molecular Biology and Evolution* **37**, 1530-1534,628doi:10.1093/molbev/msaa015 (2020).
- Kalyaanamoorthy, S., Minh, B. Q., Wong, T. K. F., von Haeseler, A. & Jermiin, L. S. ModelFinder:
 fast model selection for accurate phylogenetic estimates. *Nature Methods* 14, 587-589,
 doi:10.1038/nmeth.4285 (2017).
- Minh, B. Q., Nguyen, M. A. T. & von Haeseler, A. Ultrafast Approximation for Phylogenetic
 Bootstrap. *Molecular Biology and Evolution* **30**, 1188-1195, doi:10.1093/molbev/mst024
 (2013).
- 635 33 Sagulenko, P., Puller, V. & Neher, R. A. TreeTime: Maximum-likelihood phylodynamic analysis.
 636 *Virus evolution* 4, vex042-vex042, doi:10.1093/ve/vex042 (2018).
- 63734Bouckaert, R. *et al.* BEAST 2: a software platform for Bayesian evolutionary analysis. *PLoS*638*Comput Biol* **10**, e1003537 (2014).
- 639 35 Illingworth, C. J. SAMFIRE: multi-locus variant calling for time-resolved sequence data.
 640 *Bioinformatics* 32, 2208-2209, doi:10.1093/bioinformatics/btw205 (2016).
- 64136Martin, D. P., Murrell, B., Golden, M., Khoosal, A. & Muhire, B. RDP4: Detection and analysis642of recombination patterns in virus genomes. *Virus evolution* 1 (2015).
- 64337Didelot, X. & Wilson, D. J. ClonalFrameML: efficient inference of recombination in whole644bacterial genomes. *PLoS Comput Biol* **11**, e1004041 (2015).
- 64538Wrobel, A. G. *et al.* SARS-CoV-2 and bat RaTG13 spike glycoprotein structures inform on virus646evolution and furin-cleavage effects. Nature Structural & Molecular Biology 27, 763-767,647doi:10.1038/s41594-020-0468-7 (2020).
- 64839Gregson, J. et al. HIV-1 viral load is elevated in individuals with reverse transcriptase mutation649M184V/I during virological failure of first line antiretroviral therapy and is associated with650compensatory mutation L74I. The Journal of infectious diseases, doi:10.1093/infdis/jiz631651(2019).
- Naldini, L., Blomer, U., Gage, F. H., Trono, D. & Verma, I. M. Efficient transfer, integration, and
 sustained long-term expression of the transgene in adult rat brains injected with a lentiviral
 vector. *Proceedings of the National Academy of Sciences of the United States of America* 93,
 11382-11388 (1996).
- 65641Gupta, R. K. *et al.* Full-length HIV-1 Gag determines protease inhibitor susceptibility within in
vitro assays. *Aids* 24, 1651-1655, doi:10.1097/QAD.0b013e3283398216 (2010).

- 658 42 Mlcochova, P. et al. Combined point of care nucleic acid and antibody testing for SARS-CoV-2 659 following emergence of D614G Spike Variant. Cell Rep Med, 100099, 660 doi:10.1016/j.xcrm.2020.100099 (2020).
- 661 43 Seow, J. et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nat Microbiol 5, 1598-1607, 662 663 doi:10.1038/s41564-020-00813-8 (2020).



Figure 1. Analysis of 23 Patient derived whole SARS-CoV-2 genome sequences in context of national sequences and other cases of chronic SARS-CoV-2 shedding. A. Circularised maximum-likelihood phylogenetic tree rooted on the Wuhan-Hu-1 reference sequence, showing a subset of 250 local SARS-CoV-2 genomes from GISAID. This diagram highlights significant diversity of the case patient (green) compared to three other local patients with prolonged shedding (blue, red and purple sequences). All SARS-CoV-2 genomes were downloaded from the GISAID database and a random subset of 250 local sequences selected. **B.** Close-view maximum-likelihood phylogenetic tree indicating the diversity of the case patient and three other long-term shedders from the local area (red, blue and purple), compared to recently published sequences from Choi et al (orange) and Avanzato et al (gold). Control patients generally showed limited diversity temporally, though the Choi et al sequences were found to be even more divergent than the case patient. Environmental samples are indicated. 1000 ultrafast bootstraps were performed and support at nodes is indicated.



Figure 2. Virus genetics and population structure in chronic SARS-CoV-2 infection. A. Highlighter plot indicating nucleotide changes at consensus level in sequential respiratory samples compared to the consensus sequence at first diagnosis of COVID-19. Each row indicates the timepoint the sample was collected (number of days from first positive SARS-CoV-2 RT-PCR). Black dashed lines indicate the RNA-dependent RNA polymerase (RdRp) and Spike regions of the genome. Of particular interest, at consensus level, there were no nucleotide substitutions on days 1-57, despite the patient receiving two courses of remdesivir. The first major changes in the spike genome occurred on day 82, following convalescent plasma given on days 63 and 65. The double amino acid deletion in S1, Δ H69/V70 is indicated by black lines. All samples are nose and throat swabs unless indicated with ETA (endotracheal aspirate). **B.** Whole genome amino acid variant trajectories based on Illumina short read ultra deep sequencing at 1000x coverage. All variants which reached a frequency of at least 10% in at least two samples were plotted. Black dashed line represents Δ 69/70. CP, convalescent plasma; RDV, Remdesivir.

Figure 3



Figure 3. Longitudinal variant frequencies and phylogenetic relationships for virus populations bearing six Spike (S) mutations **A.** At baseline, all four S variants (Illumina sequencing) were absent (<1% and <20 reads). Approximately two weeks after receiving two units of convalescent plasma (CP), viral populations carrying ΔH69/V70 and D796H mutants rose to frequencies >90% but decreased significantly four days later. This population was replaced by a population bearing Y200H and T240I, detected in two samples over a period of six days. These viral populations were then replaced by virus carrying W64G and P330S mutations in Spike, which both reached near fixation at day 93. Following a 3rd course of remdesivir and an additional unit of convalescent plasma, the ΔH69/V70 and D796H virus population re-emerged to become the dominant viral strain reaching variant frequencies of >90%. Pairs of mutations arose and disappeared simultaneously indicating linkage on the same viral haplotype. **B.** Maximum likelihood phylogenetic tree of the case patient with day of sampling indicated. Spike mutations defining each of the clades are shown ancestrally on the branches on which they arose. Number at node denotes support by ultrafast bootstrapping consisting of 1000 replicates.

Figure 4



Figure 4: Spike mutant D796H + Δ H69/V70 has infectivity comparable to wild type but is less sensitive to multiple units of convalescent plasma (CP) and sera from recovered individuals. A. Reverse transcriptase activity of virus supernatants containing lentivirus pseudotyped with SARS-CoV-2 Spike protein (WT versus mutant) B. Single round Infectivity of luciferase expressing lentivirus pseudotyped with SARS-CoV-2 Spike protein (WT versus mutant) on 293T cells co-transfected with ACE2 and TMPRSS2 plasmids. C. Patient serum (taken at indicated Day (D)) and convalescent plasma (CP units 1-3) neutralization potency against Spike mutant D796H + Δ H69/V70 measured using lentivirus pseudotyped with SARS-CoV-2 Spike protein (WT versus mutant). Indicated is serum dilution required to inhibit 50% of virus infection. D. Neutralization potency of sera from 5 unselected convalescent patients (with previous confirmed SARS-CoV-2 infection) against WT versus mutant virus as in panel C. E Neutralization potency of a panel of monoclonal antibodies against lentivirus pseudotyped with SARS-CoV-2 Spike protein (WT Wuhan versus single mutants D614G, D796H, Δ H69/V70). Data are representative of at least two independent experiments * p<0.05





Figure 5. Location of Spike mutations ΔH69/Y70 in S1 and D796H in S2. Amino acid residues H69 and Y70 deleted in the N-terminal domain (red) and D796H in subunit 2 (orange) are highlighted on a SARS-CoV-2 spike trimer (PDB: 6ZGE Wrobek et al., 2020). Each of the three protomers making up the Spike homotrimer are coloured separately in shades of grey (centre). Close-ups of ΔH69/Y70 (above) and D796H (below) are shown in cartoon, stick representation. Both mutations are in exposed loops.